Published in Biotech Business Week, January 10th, 2005
The company intends to use the proceeds of the financing to fund its ongoing operations. Please refer to the company's Form 8-K filing for a complete description of the securities issued in the financing.
Under the terms of the financing, the company issued and sold 5000 shares of its Series B Preferred Stock at a purchase price of $1000 per share. Each share of Series B Preferred Stock is convertible into 2,222 shares of the company's common...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.